

**Wright Medical Group, Inc.**  
**Pro Forma Sales Growth Information**  
(unaudited)

**Fourth Quarter 2014**  
**Pro Forma**  
**Constant Currency Sales**  
**Growth <sup>(1)</sup>**

<b>U.S.</b>	
Foot and Ankle	16%
Upper Extremity	(14%)
Biologics	1%
Other	(41%)
<b>Total U.S.</b>	<b>10%</b>
<b>International</b>	
Foot and Ankle	6%
Upper Extremity	11%
Biologics	11%
Other	(1%)
<b>Total International</b>	<b>7%</b>
<b>Global</b>	
Foot and Ankle	14%
Upper Extremity	(6%)
Biologics	4%
Other	(10%)
<b>Total Sales</b>	<b>9%</b>

(1) Pro Forma Constant Currency Sales Growth is calculated as the growth of 2014 actual sales, excluding the impact of foreign currency over 2013 pro forma sales (as defined and reconciled below).

**Wright Medical Group, Inc.**  
**Pro Forma Same Day Sales Growth Information**  
(unaudited)

**Fourth Quarter 2014**  
**Pro Forma**  
**Same Day**  
**Sales Growth <sup>(1)</sup>**

<b>U.S.</b>	
Foot and Ankle	16%
Upper Extremity	(14%)
Biologics	1%
Other	(41%)
<b>Total U.S.</b>	<b>10%</b>

(1) Pro Forma Same Day Sales Growth is calculated as the growth of 2014 sales per selling day over 2013 pro forma sales (as defined and reconciled below) per selling day. We provide the number of U.S. selling days per quarter on our website at “Corporate - Investor Information - Financial Information - U.S. Selling Days.”

**Wright Medical Group, Inc.**  
**Pro Forma Sales**  
(unaudited)

	<b>Q4 2013</b>		
	<b>As Reported</b>	<b>Acquired</b>	<b>Pro Forma</b>
<b>U.S.</b>			
Foot and Ankle	33,196	6,324	39,520
Upper Extremity	4,519		4,519
Biologics	11,042	959	12,001
Other	492	252	744
<b>Total U.S.</b>	49,249	7,535	56,784
<b>International</b>			
Foot and Ankle	9,840	1,323	11,163
Upper Extremity	2,062	301	2,363
Biologics	4,818	21	4,839
Other	1,855	396	2,251
<b>Total International</b>	18,575	2,041	20,616
<b>Global</b>			
Foot and Ankle	43,036	7,647	50,683
Upper Extremity	6,581	301	6,882
Biologics	15,860	980	16,840
Other	2,347	648	2,995
<b>Total Sales</b>	67,824	9,576	77,400

(1) Pro Forma revenues are calculated from adding revenues recognized by Biotech, Solana and OrthoPro prior to our acquisition of these businesses to our reported revenues in each respective period of 2013.

**Wright Medical Group, Inc.**  
**Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency**  
(dollars in thousands--unaudited)

	<b>Three Months Ended December 31, 2014</b>		<b>Twelve Months Ended December 31, 2014</b>	
	<b>International Net Sales</b>	<b>Total Net Sales</b>	<b>International Net Sales</b>	<b>Total Net Sales</b>
<b>Net sales, as reported</b>	\$ 20,808	\$ 83,294	\$ 85,950	\$ 298,027
Currency impact as compared to prior period	1,220	1,220	644	644
<b>Net sales, excluding the impact of foreign currency</b>	\$ 22,028	\$ 84,514	\$ 86,594	\$ 298,671

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2014	December 31, 2013	December 31, 2014	December 31, 2013
<b>Operating Income</b>				
<b>Operating loss, as reported</b>	\$ (26,940)	\$ (23,240)	\$ (99,806)	\$ (282,206)
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	14	278	1,535	777
BioMimetic inventory write-down	—	1,301	—	2,280
Total	14	1,579	1,535	3,057
<i>Reconciling items impacting Selling, General and Administrative expense:</i>				
Distributor conversions	14	129	186	932
Transition costs - OrthoRecon divestiture	1,425	7,745	5,849	21,612
Due diligence, transaction and transition costs - acquisitions <sup>(1)</sup>	2,509	2,270	14,115	12,893
Patent dispute settlement	—	—	900	—
Management changes <sup>(2)</sup>	—	—	1,203	—
Tornier merger costs	11,900	—	11,900	—
Total	15,848	10,144	34,153	35,437
<i>Reconciling items impacting Amortization of Intangible Assets:</i>				
Amortization of distributor non-competes	359	630	1,885	2,802
<i>Other Reconciling Items:</i>				
BioMimetic impairment charges	—	—	—	206,249
<b>Operating loss, as adjusted</b>	\$ (10,719)	\$ (10,887)	\$ (62,233)	\$ (34,661)
<b>Operating loss, as adjusted, as a percentage of net sales</b>	(12.9)%	(16.1)%	(20.9)%	(14.3)%

(1) For the twelve months ended December 31, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

(2) For the twelve months ended December 31, 2014, amount includes \$0.3 million of non-cash stock-based compensation expense related to the management changes.

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	<u>Three Months Ended</u>		<u>Twelve Months Ended</u>	
	<u>December 31, 2014</u>	<u>December 31, 2013</u>	<u>December 31, 2014</u>	<u>December 31, 2013</u>
<b>EBITDA</b>				
<b>Net loss, as reported</b>	\$ (106,968)	\$ (135,211)	\$ (240,496)	\$ (280,168)
Interest expense, net	4,525	4,061	17,398	16,040
Provision (benefit) for income taxes	863	110,462	(6,334)	49,765
Depreciation	4,961	4,120	18,456	14,384
Amortization of intangible assets	2,786	1,750	10,027	7,476
<b>EBITDA</b>	<u>(93,833)</u>	<u>(14,818)</u>	<u>(200,949)</u>	<u>(192,503)</u>
<i>Reconciling items impacting EBITDA</i>				
Non-cash stock-based compensation expense <sup>(1)(2)</sup>	2,519	2,481	11,204	9,658
Other expense (income), net	74,640	(2,552)	129,626	(67,843)
Inventory step-up amortization	14	278	1,535	777
Distributor conversions	14	129	186	932
Due diligence, transaction and transition costs	3,934	10,015	19,964	34,505
BioMimetic impairment and other charges	—	1,301	—	208,529
Patent dispute settlement	—	—	900	—
Management changes	—	—	1,203	—
Tornier merger costs	11,900	—	11,900	—
<b>Adjusted EBITDA</b>	<u>\$ (812)</u>	<u>\$ (3,166)</u>	<u>\$ (24,431)</u>	<u>\$ (5,945)</u>
<b>Adjusted EBITDA as a percentage of net sales</b>	<u>(1.0)%</u>	<u>(4.7)%</u>	<u>(8.2)%</u>	<u>(2.5)%</u>

(1) For the twelve months ended December 31, 2013, amount excludes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options, which is included in due diligence, transaction and transition costs.

(2) For the twelve months ended December 31, 2014, amount excludes \$0.3 million of non-cash stock-based compensation expense related to the management changes, which is included in management changes.

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2014	December 31, 2013	December 31, 2014	December 31, 2013
<b>Net Income</b>				
<b>Loss before taxes, as reported</b>	\$ (106,105)	\$ (24,749)	\$ (246,830)	\$ (230,403)
<i>Pre-tax impact of reconciling items:</i>				
Inventory step-up amortization	14	278	1,535	777
Distributor conversion and non-competes	373	759	2,071	3,734
Non-cash interest expense on 2017 Convertible Notes	2,371	2,222	9,257	8,678
Derivatives mark-to-market adjustment	—	(2,000)	2,000	1,000
Transition costs - OrthoRecon divestiture	1,425	7,745	5,849	21,612
Due diligence, transaction and transition costs <sup>(1)</sup>	2,509	2,270	14,115	12,893
BioMimetic impairment and other charges and CVR mark-to-market adjustments	73,718	460	125,011	147,381
Patent dispute settlement	—	—	900	—
Management changes <sup>(2)</sup>	—	—	1,203	—
Contingent consideration fair value adjustment	58	—	1,808	—
Tornier merger costs	11,900	—	11,900	—
Gain on previously held investment in BioMimetic	—	—	—	(7,798)
<b>Loss before taxes, as adjusted</b>	<u>(13,737)</u>	<u>(13,015)</u>	<u>(71,181)</u>	<u>(42,126)</u>
<b>Provision (benefit) for income taxes, as reported</b>	\$ 863	\$ 110,462	\$ (6,334)	\$ 49,765
U.S. tax impact resulting from gain in discontinued operations	(2,487)	—	5,453	—
Valuation allowance	—	(119,623)	—	(119,623)
Tax effect of all other items	755	4,025	755	52,952
<b>Benefit for income taxes, as adjusted</b>	<u>\$ (869)</u>	<u>\$ (5,136)</u>	<u>\$ (126)</u>	<u>\$ (16,906)</u>
<b>Effective tax rate, as adjusted</b>	<u>6.3%</u>	<u>39.5%</u>	<u>0.2%</u>	<u>40.1%</u>
<b>Net loss, as adjusted</b>	<u>\$ (12,868)</u>	<u>\$ (7,879)</u>	<u>\$ (71,055)</u>	<u>\$ (25,220)</u>
<b>Weighted-average number of shares outstanding-diluted</b>	\$ 50,698	\$ 46,897	\$ 49,758	\$ 45,265
<b>Net loss from continuing operations, as adjusted, per diluted share</b>	<u>\$ (0.25)</u>	<u>\$ (0.17)</u>	<u>\$ (1.43)</u>	<u>\$ (0.56)</u>

(1) For the twelve months ended December 31, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

(2) For the twelve months ended December 31, 2014, amount includes \$0.3 million of non-cash stock-based compensation expense related to the management changes.

**Wright Medical Group, Inc.**  
**Reconciliation of Free Cash Flow**  
(dollars in thousands--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2014	December 31, 2013	December 31, 2014	December 31, 2013
Net cash (used in) provided by operating activities	(29,850)	(42,322)	(116,002)	(36,601)
Capital expenditures	(12,897)	(15,018)	(48,603)	(37,530)
Free cash flow	(42,747)	(57,340)	(164,605)	(74,131)